Treatment effects of denosumab on refracture and mortality in elderly patients following p

379 elderly Chinese patients were observed over three years in a retrospective study from Zhongshan Hospital, Fudan University. The data compares outcomes between patients receiving denosumab treatment and a control group following primary osteoporotic hip fracture surgery. Yuzhu Wang authored this dataset, which was last updated on April 4, 2026.

Use Cases

• Compare refracture risk between treatment and control groups based on the reported subhazard ratios.
• Analyze mortality rates post-surgery based on the reported hazard ratios.
• Investigate treatment effectiveness across different age subgroups (65-84 and 85+ years) mentioned in the study.
• Validate statistical methods like Propensity Score Matching (PSM) and Inverse Probability of Treatment Weighting (IPTW) used to adjust group differences.

Strengths

• Includes data for 379 patients observed over a three-year period.
• Provides specific outcome metrics: a 13.4% refracture rate in the treatment group vs. 38.3% in the control group.
• Reports statistically significant hazard ratios (HR=0.45 for mortality, SHR=0.37 for refracture) from the analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data reflects a single-hospital study in China, which may limit generalizability to other populations.

Provenance

Source

Zhongshan Hospital, Fudan University

Collection Method

Retrospective observational study using Propensity Score Matching (PSM) and Inverse Probability of Treatment Weighting (IPTW).

Time Range

Patients treated between January 2020 and December 2021, with outcomes observed over three years.

Freshness

Last updated 2026-04-04 13:43:34; freshness should be verified.

Geography

China (Shanghai, Zhongshan Hospital)